



Tetraphase Pharmaceuticals
Investor Relations Department
480 Arsenal Street, Suite 110
Watertown, MA 02472
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: TTPH

Last Trade:	6.55
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	-0.29 ↓ (-4.240%)
Day Range	6.51 - 6.85
52-Week Range	3.11 - 9.93
Volume	1,060,780


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

Sep 11, 2017
[Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections](#)

Sep 5, 2017
[Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences](#)

Aug 17, 2017
[Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency](#)

Aug 2, 2017
[Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements](#)

Jul 27, 2017
[Tetraphase Announces Pricing of Public Offering of Common Stock](#)

Upcoming Events [\[View all \]](#)

Sep 25, 2017 1:50 PM ET
[Cantor Fitzgerald Global Healthcare Conference](#)

Financials & Filings [\[View all \]](#)

Mar 13, 2017
[Annual Report \(10-K\)](#)

Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 2, 2017
[Quarterly Report \(10-Q\)](#)

May 8, 2017
[Quarterly Report \(10-Q\)](#)

Nov 3, 2016
[Quarterly Report \(10-Q\)](#)